Selectivity Profile of the Tyrosine Kinase 2 Inhibitor Deucravacitinib Compared with Janus Kinase 1/2/3 Inhibitors
DERMATOLOGY AND THERAPY（2021）
Key words
Baricitinib,Cmax,Cytokine signaling,Deucravacitinib,IC50,Immune-mediated inflammatory disease,Janus kinase signal transducer,Tofacitinib,TYK2,Upadacitinib
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined